Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

A happy couple looking at an iPad.

Image source: Getty Images

BHP Group Ltd (ASX: BHP)

According to a note out of Goldman Sachs, its analysts have retained their buy rating on this mining giant's shares with a slightly reduced price target of $49.20. Goldman Sachs has been running the rule over the mining sector ahead of the release of quarterly updates this month. It believes BHP will deliver a reasonably solid quarterly update. For example, the broker expects copper and metallurgical coal production to increase quarter on quarter. But the main reasons the broker is positive are BHP's attractive valuation, its optionality with a +US$20 billion copper pipeline and strong production growth, and its robust free cash flow generation. The BHP share price was trading at $44.35 on Friday.

Mesoblast Ltd (ASX: MSB)

A note out of Bell Potter reveals that its analysts have retained their speculative buy rating on this cellular medicines developer's shares with an increased price target of $1.40. Bell Potter points out that the FDA has informed Mesoblast that available clinical data from a Phase 3 study for children with steroid refractory acute graft versus host disease appears sufficient to support a resubmission of the Biological Licence Application for its Remestemcel product. It believes the timing of the correspondence is no coincidence. The broker highlights that there is refreshed leadership at the newly formed Office of Therapeutic Products at the FDA. In light of this, its analysts have renewed confidence for a prospective approval of Remestemcel later this year. It also feels that a first approval may represent a gateway to a series of label expansions in the ensuing period. The Mesoblast share price was fetching 86.5 cents at the end of the week.

Treasury Wine Estates Ltd (ASX: TWE)

Analysts at UBS have retained their buy rating on this wine giant's shares with an improved price target of $15.25. This follows confirmation that the Chinese Ministry of Commerce (MOFCOM) is removing tariffs from Australian wine imports into China. According to the note, UBS was pleased with the news and believes that Treasury Wine's shares now deserve to trade on higher earnings multiples. Especially given that this news increases its addressable market. Its analysts have also lifted their earnings estimates to reflect the news and higher margin assumptions for its premium wine. The Treasury Wine share price ended the week at $12.86.

Motley Fool contributor James Mickleboro has positions in Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

Macquarie shares: Buy, hold or sell?

Two top analysts offer their outlook for Macquarie’s outperforming shares.

Read more »

A steel worker peers out from under his protective headwear which is tipped back on his head as he stares solemnly straight ahead with steel production equipment in the background.
Broker Notes

Bell Potter says this beaten-down ASX materials stock can rise 56%

Down 17% this year, Bell Potter says ASX materials stock has significant upside.

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Broker Notes

This ASX small-cap is tipped to almost double in the next year

Bell Potter just raised its guidance on this ASX small-cap.

Read more »

Man sits smiling at a computer showing graphs.
Broker Notes

6 ASX 200 shares with strengthened buy ratings this week

Brokers have maintained confidence in these ASX 200 stocks amid today's volatile market conditions.

Read more »

A happy person clenching fists in celebration sitting at computer.
Broker Notes

Morgans says hold BHP shares and buy this ASX 200 stock      

Let's see what the broker is saying about these stocks this week.

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Broker Notes

3 ASX 200 shares just upgraded to strong buy — here's what the brokers are saying

Do any of these ASX 200 stocks appeal to you?

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Two men look excited on the trading floor as they hold telephones to their ears and one points upwards.
Broker Notes

Buy, hold, sell: Sigma Healthcare, Macquarie, Santos shares

Brokers reveal their latest ratings and reviews on 3 ASX 200 stocks.

Read more »